![]() The majority of TCL cases are CD4 +, with far fewer cases being CD8 + or CD4 - CD8. TCL phenotypes can be categorized by expression of the surface antigen molecules CD4 and CD8. The most common types of TCL in dogs involving peripheral lymph nodes include indolent T-zone lymphoma (TZL) and biologically aggressive peripheral T-cell lymphoma (PTCL). She provides freelance medical writing and aquatic veterinary consulting services through her business, Seastar Communications and Consulting.Canine T-cell lymphoma (TCL) encompasses a heterogeneous group of diseases with variable clinical presentation, cytomorphology, immunophenotype, and biologic behaviour. Stilwell received her DVM from Auburn University, followed by a MS in Fisheries and Aquatic Sciences and a PhD in Veterinary Medical Sciences from the University of Florida. Therefore, the authors concluded that modified LOPP protocol is a viable treatment option for high-grade T-cell lymphoma in dogs.ĭr. Toxicity, however, was less frequently observed compared to other therapies. Additionally, the overall survival times in this study were comparable to those observed with other chemotherapy options for T-cell lymphoma. While a high response rate was observed with modified LOPP chemotherapy, response was typically of limited duration. Four of 31 dogs were hospitalized for side effects during the course of the study. Adverse effects included hepatotoxicity from lomustine use (26%), myelosuppression (23%), and gastrointestinal signs (19%). ![]() Modifications to the LOPP protocol, including the increased vincristine dose interval and separate administration of lomustine, appeared to reduce toxicity issues commonly reported with LOPP chemotherapy. All deaths in the study were attributable to lymphoma. Survival rates after LOPP chemotherapy were 39% for 1 year and 25% for 2 years. The median disease-free interval-defined as the time between first documented remission and relapse-was 176 days (range 37-1745 days). Ninety percent of the study’s dogs experienced complete remission of T-cell lymphoma after chemotherapy, while 7% and 3% experienced partial or no response to therapy, respectively. Seventy-four percent of participants completed the intended LOPP protocol, consisting of 6 cycles over 24 weeks. ![]() T-cell lymphoma was diagnosed via immunocytochemistry for 28 of the dogs and immunohistochemistry for 3 dogs.Īll dogs were treated with the modified LOPP protocol, which also included l-asparaginase induction for 13 of 31 dogs. Of the dogs that met the inclusion criteria for the study, the median age of participants was 7 years and median weight was 26 kg. The authors also determined the presence and grade of toxicity during each treatment cycle via veterinary examination and the completion of an owner questionnaire. Response was classified as complete remission (resolution of all clinically-detectable disease), partial response, or no response. Treatment response was evaluated every 14 days through physical examination, hematology, and biochemistry results.
0 Comments
Leave a Reply. |